SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma is trending as investors weigh its potential for massive growth in silicon photonics against the execution risks associated with its transition from early-stage government contracts to commercial-scale manufacturing. Community sentiment is sharply divided between those bullish on its proprietary 300mm wafer technology as a high-reward play and those skeptical of its current revenue levels and recurring share offerings.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is gaining significant momentum as investors digest recent FDA Orphan Drug Designations and progress in late-stage Phase 3 clinical trials for its pancreatic cancer therapy. The community is actively discussing the stock's potential for a major re-rating, with analysts increasingly highlighting the company's robust pipeline and strategic importance in targeted oncology.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is trending due to the resignation of its top lawyer amid revelations of ongoing ties to Jeffrey Epstein, triggering a sharp decline in share price. Investors are also closely monitoring the bank's exposure to volatile credit markets and broader concerns regarding institutional stability during a period of geopolitical uncertainty.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF is experiencing intense volatility and heightened scrutiny as traders debate whether current valuation levels represent a sustainable AI-driven growth cycle or an overheated bubble. The community is actively tracking a sharp divergence between high-flying hardware momentum and a struggling software sector, while aggressive options activity and short-dated put sweeps suggest that institutional players are bracing for significant downside risks.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is seeing heavy retail and institutional interest as investors bet on the companys electro-optic polymer technology as a scalable solution for AI data centers. The community is actively debating the transition from R&D to foundry-integrated manufacturing, with recent partnerships and expectations of upcoming tape-out results driving volatility and ongoing speculation about potential major industry acquisitions.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing intense investor interest and volatility driven by its role in the AI infrastructure supply chain and significant follow-on orders for optical transceivers. While bulls highlight rapid revenue scaling and demand in the photonics sector, the community remains sharply divided, with active debates centered on whether recent parabolic price moves are justified by fundamentals or represent a speculative bubble ripe for a short squeeze.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is surging following positive Phase 2/3 trial results for its metastatic uveal melanoma treatment, which significantly improved progression-free survival compared to standard therapies. Investors and the community are actively debating the potential for an accelerated FDA filing, while also closely watching for future pipeline updates and high institutional interest.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing significant market interest driven by a combination of high trading volume, a short squeeze, and momentum following its expansion and integration with the USD1-denominated ecosystem. While some community members are actively debating the token's long-term utility and governance, others are focused on its rapid price action and speculative potential as a trending Web3 entertainment protocol.

Maulcoin

Maulcoin is trending as a community-driven, Star Wars-themed meme coin, with supporters actively lobbying for a price chart on major platforms while sharing their experiences with holding through volatility. The community remains focused on collective buying efforts and long-term holding to drive up market capitalization, frequently highlighting the project's growth and their commitment to building a lasting cultural presence.

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Spyre Therapeutics Inc.

Aeglea BioTherapeutics Inc

Spyre Therapeutics is seeing significant investor interest following positive clinical data for its SPY001 program, with the community actively discussing the company's multi-pathway platform approach and its potential to disrupt the IBD market. While some investors are focused on the long-term potential of its upcoming pipeline milestones, others remain cautious regarding the risks typically associated with clinical-stage biotechnology companies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai the World's First Multi-Agentic Co-Scientist for Rare Cancers 8:30 AM Eastern, April 9, 2026

Lantern Pharma Inc. (Nasdaq: LTRN) (Lantern or the Company), an AI-driven clinical-stage precision oncology company, today announced it will host an investor, analyst and shareholder briefing on...

AI and Biotech Enter a Stock Picker’s Market

The market is sending a mixed but telling signal: innovation is accelerating, but only the most disciplined and well-positioned companies are keeping pace. Across AI, biotech, and micro-cap tech, recent developments highlight a widening divide between firms gaining validation and those fighting to maintain footing in public markets. $BFRG, $TGNT, $LTRN, $VRAX, $KIDZ, $HKIT

Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR artificial intelligence (AI) and machine learning (ML) platform to transform the cost...

Why Is Lantern Pharma Stock Soaring Monday?

Lantern Pharma shares rebound in premarket trading as the company debunks a false report regarding CEO Panna Sharma's departure.read more...

<ul class="summary-bullets"><li>PMGC Holdings said Friday that its unit, NorthStrive Biosciences, amended a deal with MOA Life Plus to run human trials for EL-22 and EL-32, targeting muscle and lean mass preservation.</li><li>Iterum Therapeutics announced on Friday that it had filed a winding-up petition in Ireland, which is set to be heard on April 13, 2026.</li><li>Lantern Pharma said the FDA cleared its Investigational New Drug application for STAR-001, a targeted therapy for relapsed or refractory CNS cancers.</li></ul>U.S. equities were in the green in Monday’s pre-market trade amid the ongoing tensions in the Middle East, with President Donald Trump stating on Sunday that Iran had agreed to the 15-point ceasefire plan “for the most part.”At the time of writing, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which tracks the S&amp;P 500 index, was up 0.49%; the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust ETF</a> (QQQ) rose 0.42%; and the&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA) gained 0.47%. Retail sentiment on Stocktwits regarding the S&amp;P 500 ETF was in the ‘extremely bearish’ territory.<h2 class="st-heading-2">Here are the top stocks making the biggest moves in Monday’s pre-market trade:</h2><a href="https://stocktwits.com/symbol/ELAB">PMGC Holdings Inc. (ELAB)</a>PMGC Holdings shares soared more than 66% in Monday’s pre-market session. The company announced on Friday that its wholly-owned subsidiary, NorthStrive Biosciences, has amended its existing agreement with MOA Life Plus for human clinical trials of its lead candidate EL-22, as well as EL-32, to study the preservation of muscle and lean mass.<a href="https://stocktwits.com/symbol/ELAB">ELAB stock</a> is down 95% year-to-date.<a href="https://stocktwits.com/symbol/ITRM">Iterum Therapeutics PLC (ITRM)</a>Iterum Therapeutics shares more than doubled to soar 110% in Monday’s pre-market trade. The company announced on Friday that it had filed a winding-up petition in Ireland, which is set to be heard on April 13, 2026.<a href="https://stocktwits.com/symbol/ITRM">ITRM stock</a> is down 90% year-to-date.<a href="https://stocktwits.com/symbol/LTRN">Lantern Pharma Inc. (LTRN)</a>Lantern Pharma shares gained more than 17% in Monday’s pre-market session. The company announced on Friday that its CEO Panna Sharma continues to serve the Dallas-based biopharmaceutical company. It also announced that the U.S. Food and Drug administration (FDA) cleared its Investigational New Drug (IND) application for STAR-001, its treatment for patients with relapsed or refractory central nervous system (CNS) malignancies.<a href="https://stocktwits.com/symbol/LTRN">LTRN stock</a> is down 63% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bur-stock-sinks-after-us-appeals-court-ruling-argentina-ypf-connection/cZ3HJ4aRIm7">BUR Stock Sinks 40% Following A Reported US Appeals Court Ruling — What Is The Argentina Connection?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Top Pre-Market Gainers Today — ELAB, ITRM, LTRN Among Stocks Soaring Before The Bell

U.S. equities gained in Monday’s pre-market trade after President Donald Trump stated that Iran had agreed to the 15-point proposal for the most part.

Equity

Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report

Lantern Pharma Inc. (NASDAQ: LTRN) (Lantern or the Company), an AIdriven, clinicalstage oncology company leveraging its proprietary RADR platform to transform the cost and timeline of cancer drug development, today issued the following statement in response to an article published earlier today on...

Lantern Pharma Stock Falls 10% After FDA Clears Investigational New Drug Application For STAR-001

(RTTNews) - Stock of Lantern Pharma Inc. (LTRN) is moving down about 10 percent on Friday morning trading after the company, along with its subsidiary Starlight Therapeutics, announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application...

AI, Biotech, and Biologics Drive Big Narratives

A new wave of healthcare innovation, powered by artificial intelligence, next-generation biologics, and shifting regulatory pathways, is colliding with market dynamics to create both breakthrough potential and high-volatility trading setups. $ARTL, $TGNT, $ADMA, $RCKT, $LTRN, $GCTK

<ul class="summary-bullets"><li>STAR-001 is a precision oncology compound discovered using Lantern’s proprietary RADR AI platform.</li><li>The study will evaluate the drug both as a standalone treatment and in combination with Spironolactone.</li><li>The trial to be conducted with the Pediatric Oncology Experimental Therapeutics Investigators' Consortium.</li></ul>Shares of Lantern Pharma Inc. (LTRN) surged nearly 18% in pre-market trading on Friday after the biotech firm said that the U.S. Food and Drug Administration cleared its Investigational New Drug (IND) application for STAR-001, allowing the company to begin a Phase 1 pediatric clinical trial for central nervous system cancers.STAR-001 is a precision oncology compound discovered using Lantern’s proprietary RADR AI platform, which helped identify its potential in CNS and pediatric CNS indications, the company said. The study will evaluate the drug both as a standalone treatment and in combination with Spironolactone in children with relapsed or refractory CNS cancers.The trial will be conducted in collaboration with the Pediatric Oncology Experimental Therapeutics Investigators' Consortium.<h2 class="st-heading-2">Lantern's Drug To Treat Soft Tissue Sarcomas</h2>Earlier this year, the FDA granted Orphan Drug Designation to Lantern Pharma's experimental drug LP-284 for the treatment of soft tissue sarcomas. It marked the third orphan designation for LP-284 and the sixth across the company’s pipeline.Orphan designation provides incentives to support the development of treatments for rare diseases affecting fewer than 200,000 people in the U.S.LP-284 is a small-molecule therapy designed to target cancer cells with DNA repair defects. The drug has shown encouraging activity in early studies, including a complete response in a heavily pretreated lymphoma patient in a Phase 1 trial.The therapy is currently being tested in patients with B-cell non-Hodgkin lymphomas.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/LTRN">LTRN</a> on Stocktwits turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.<img src="https://news.stocktwits-cdn.com/LTRN_jpg_fb27c74f09.webp" alt="LTRN.jpg">The stock has been under heavy selling pressure, slumping more than 50% in 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

LTRN Stock Gains 18% Pre-Market: FDA Greenlights First Pediatric Cancer Trial For Oncology Compound

The U.S. Food and Drug Administration cleared its Investigational New Drug application for Lantern Pharma’s oncology compound, paving the way for a Phase 1 clinical trial.

Why Did LTRN Stock Surge 18% In Pre-Market Today? 

Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001

Lantern Pharma Inc. (NASDAQ: LTRN) and its CNS-oncology focused wholly owned subsidiary Starlight Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared the...

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.

Current Price	$1.97
Prev Close	$1.87
Open	$1.92
Dividend Yield	0.00%
50-Day Moving Average	$2.44
Beta	1.83
Avg. Volume	1.22M
PE Ratio	-1.25

52-Week High	$5.74
52-Week Low	$1.11
Market Capitalization	$22.17M
EPS (Annual)	-$1.57
Price to Book	3.39
Revenue Per Employee	$0.00

LTRN
Lantern Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LTRN News

LTRNLantern Pharma Inc